The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

HHS rehired more than 700 workers at the CDC and over 200 employees at the NIH after restructuring this spring, HHS Secretary ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Our strategic approach is about advancing science to benefit patients most in need of new therapies. As a private company led ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...